Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.73 |
| ▸ | CTSK | P43235 | 3/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.56 |
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270141 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL29907906 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL29401585 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL270319 | 1.00 | CTSS (0.73) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL23722980 | 0.90 | CTSS (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL4663077 | 0.87 | CTSK (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL8238593 | 0.87 | CTSK (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL13743658 | 0.87 | CTSK (0.60) | CTSSCTSKPTPN1ACESCN9A | |
| SCHEMBL12851291 | 0.87 | CTSS (0.73) | CTSSCTSKPTPN1SCN9ASCN10A | |
| SCHEMBL3006752 | 0.86 | CTSS (0.55) | CTSSCTSKPTPN1ACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| US-20200383327-A1 | METHOD OF IMPROVING PLANT PERFORMANCE | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2020-12-10 | — | — | US | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190246639-A1 | METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCHORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2019-08-15 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| EP-2655322-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | Diverchim (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0866705-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5852045-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| EP-0866705-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | CTSS 2319/4885CTSK 1324/4885PTPN1 4478/4885 |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | CTSS 2857/4885CTSK 2898/4885PTPN1 2035/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | CTSS 2520/4885CTSK 2560/4885PTPN1 2335/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | CTSS 2636/4885CTSK 1778/4885PTPN1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.